Wael Yared
Chief Tech/Sci/R&D Officer at TECAN GROUP AG
Net worth: 876 374 $ as of 2024-04-29
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Andreas Wilhelm | M | 55 | 20 years | |
Ulrich Kanter | M | 61 | 10 years | |
Martin Brändle | M | 53 | 16 years | |
Achim von Leoprechting | M | 56 | 11 years | |
Daniel Marshak | M | 67 | 6 years | |
Ingrid Pürgstaller | F | 44 | 4 years | |
Ralf Griebel | M | 52 | 4 years | |
Myra Eskes | F | - | 2 years | |
Tania Micki | F | 52 | 4 years | |
Erik Norström | M | 50 | 7 years | |
Klaus Lun | M | 52 | 11 years | |
Lukas Braunschweiler | M | 68 | 6 years | |
Christa Kreuzburg | M | 65 | 11 years | |
Günter Weisshaar | M | 64 | 21 years | |
Oliver Fetzer | M | 60 | 13 years | |
Karen Hübscher | M | 61 | 12 years | |
Matthias Gillner | M | 57 | 1 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Guy L. Mayer | M | 72 |
VisEn Medical, Inc.
VisEn Medical, Inc. Medical/Nursing ServicesHealth Services VisEn's in vivo fluorescence imaging technologies, including its Fluorescence Agent Portfolio and its Fluorescence Molecular Tomographic (FMTTM) Imaging Systems provide robust fluorescence molecular imaging performance in identifying, characterizing and quantifying ranges of disease biomarkers and therapeutic efficacy in vivo. VisEn's FMT systems and agents are used by leading research institutions and pharmaceutical companies in applications including cancer research, inflammation, cardiovascular, skeletal and pulmonary disease. The company also works with large pharmaceutical partners to design ranges of tailored molecular imaging agents and applications that are designed to their specific pre-clinical and clinical research areas. | 3 years |
Markus Schmid | M | 56 | 9 years | |
Harry Wilcox | M | 69 |
VisEn Medical, Inc.
VisEn Medical, Inc. Medical/Nursing ServicesHealth Services VisEn's in vivo fluorescence imaging technologies, including its Fluorescence Agent Portfolio and its Fluorescence Molecular Tomographic (FMTTM) Imaging Systems provide robust fluorescence molecular imaging performance in identifying, characterizing and quantifying ranges of disease biomarkers and therapeutic efficacy in vivo. VisEn's FMT systems and agents are used by leading research institutions and pharmaceutical companies in applications including cancer research, inflammation, cardiovascular, skeletal and pulmonary disease. The company also works with large pharmaceutical partners to design ranges of tailored molecular imaging agents and applications that are designed to their specific pre-clinical and clinical research areas. | - |
Erik Walldén | M | 75 |
VisEn Medical, Inc.
VisEn Medical, Inc. Medical/Nursing ServicesHealth Services VisEn's in vivo fluorescence imaging technologies, including its Fluorescence Agent Portfolio and its Fluorescence Molecular Tomographic (FMTTM) Imaging Systems provide robust fluorescence molecular imaging performance in identifying, characterizing and quantifying ranges of disease biomarkers and therapeutic efficacy in vivo. VisEn's FMT systems and agents are used by leading research institutions and pharmaceutical companies in applications including cancer research, inflammation, cardiovascular, skeletal and pulmonary disease. The company also works with large pharmaceutical partners to design ranges of tailored molecular imaging agents and applications that are designed to their specific pre-clinical and clinical research areas. | - |
David Roy Martyr | M | 67 | 7 years | |
Heinrich Fischer | M | 74 | 16 years | |
John Ziolkowski | M | - |
VisEn Medical, Inc.
VisEn Medical, Inc. Medical/Nursing ServicesHealth Services VisEn's in vivo fluorescence imaging technologies, including its Fluorescence Agent Portfolio and its Fluorescence Molecular Tomographic (FMTTM) Imaging Systems provide robust fluorescence molecular imaging performance in identifying, characterizing and quantifying ranges of disease biomarkers and therapeutic efficacy in vivo. VisEn's FMT systems and agents are used by leading research institutions and pharmaceutical companies in applications including cancer research, inflammation, cardiovascular, skeletal and pulmonary disease. The company also works with large pharmaceutical partners to design ranges of tailored molecular imaging agents and applications that are designed to their specific pre-clinical and clinical research areas. | - |
Rudolf Eugster | M | 59 | 18 years |
Statistics
Country | Connections | % of total |
---|---|---|
Switzerland | 21 | 84.00% |
United States | 4 | 16.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Wael Yared
- Personal Network